Study shows 57% reduction in carcinogen exposure within one week of switching to vaping
Anti-vaping activists and Big Tobacco lobbyists often confuse the general public by making false claims that vaping is equally as deadly as smoking. Since scientists have been sounding the alarm for decades that smoking is highly carcinogenic, the incorrect assumption is being made by the average citizen that vaping also causes cancer.
However, a recent study conducted by researchers at Roswell Park Institute in Buffalo, New York, indicates that smokers who switch to vaping show a significant decrease in carcinogenic exposure of at least 57 percent within the first 7-days and approximately 64 percent within the first two-weeks. The study entitled Exposure to Nicotine and Selected Toxicants in Cigarette Smokers Who Switched to Electronic Cigarettes: A Longitudinal Within-Subjects Observational Study (NCBI) is led by tobacco control specialist Dr. Maciej Goniewicz.
Overview of the Goniewicz study
The research team initially set out to determine the differences in nicotine exposure between smoking versus vaping, but as their clinical trial evolved, they stumbled upon some rather unexpected findings. The researchers began by carefully selecting a control group of twenty participants. Each had a long history of daily smoking, and each agreed to make a complete switch to vaping. No dual usage was allowed.
Throughout the experiment, the scientists monitored the vaping habits of each participant while simultaneously tracking multiple biomarkers. Through both urinary and blood sample analysis, the goal was to compare the differing exposure levels of nitrosamines, carcinogens, volatile organic compounds, polycyclic aromatic hydrocarbons, metals, metabolites, and various toxins associated with combustible cigarettes. To the researchers’ astonishment, the average levels of carcinogenic exposure had plummeted by a whopping 57 percent after just one week.
“In total, 45% of participants reported complete abstinence from cigarette smoking at 2 weeks, while 55% reported continued smoking. Levels of total nicotine and some polycyclic aromatic hydrocarbon metabolites did not change after switching from tobacco to e-cigarettes. All other biomarkers significantly decreased after 1 week of using e-cigarettes (p < .05). After 1 week, the greatest percentage reductions in biomarkers levels were observed for metabolites of 1,3-butadiene, benzene, and acrylonitrile. Total NNAL, a metabolite of NNK, declined by 57% and 64% after 1 and 2 weeks, respectively, while 3-hydroxyfluorene levels declined by 46% at week 1, and 34% at week 2.”
Of the twenty original participants, over half were expelled from the trial for failing to fully transition to vapes. However, about 45 percent were successful in quitting smoking permanently which, in itself, is a significant figure. A success rate of this magnitude is substantially higher than current statistics surrounding the more conventional nicotine replacement therapies (NRTs) of patches, gums, and lozenges.
In fact, the Roswell study seems to confirm the findings of a prior unrelated randomized clinical trial whose results were published in the New England Journal of Medicine in February 2019. In the later study, vaping proved to be approximately twice as effective in quitting smoking compared to other NRTs manufactured and marketed by Big Pharma.
(Image courtesy of Shutterstock)